+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dulaglutide"

Dulaglutide Market Report 2025 - Product Thumbnail Image

Dulaglutide Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Non-Insulin Therapies for Diabetes Market Report 2025 - Product Thumbnail Image

Non-Insulin Therapies for Diabetes Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
Type 2 Diabetes Market Report 2025 - Product Thumbnail Image

Type 2 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Incretin-Based Drugs Global Market Report 2025 - Product Thumbnail Image

Incretin-Based Drugs Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
From
Antidiabetics Market Report 2025 - Product Thumbnail Image

Antidiabetics Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
Trulicity - Global Strategic Business Report - Product Thumbnail Image

Trulicity - Global Strategic Business Report

  • Report
  • August 2025
  • 471 Pages
  • Global
From
From
GLP-1 Agonists Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

GLP-1 Agonists Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Diabetes Drug Market Overview, 2025-30 - Product Thumbnail Image

Diabetes Drug Market Overview, 2025-30

  • Report
  • June 2025
  • 109 Pages
  • Global
From
From
From
From
From
Loading Indicator

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. It is a long-acting injectable medication that helps to reduce blood sugar levels by increasing insulin production and decreasing glucagon production. It also helps to reduce appetite and promote weight loss. Dulaglutide is approved by the US Food and Drug Administration (FDA) for use in adults with type 2 diabetes and is available in both brand and generic forms. Dulaglutide is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions such as diabetes, obesity, thyroid disorders, and other endocrine and metabolic disorders. The market is expected to grow due to increasing prevalence of endocrine and metabolic disorders, rising awareness of the importance of early diagnosis and treatment, and the availability of new treatments. Some companies in the Dulaglutide market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Show Less Read more